Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report … JJM Van Dongen, AW Langerak, M Brüggemann, PAS Evans, M Hummel, ... Leukemia 17 (12), 2257-2317, 2003 | 3685 | 2003 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label … T Waddell, I Chau, D Cunningham, D Gonzalez, AFC Okines, ... The lancet oncology 14 (6), 481-489, 2013 | 845 | 2013 |
Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial EC Smyth, A Wotherspoon, C Peckitt, D Gonzalez, S Hulkki-Wilson, ... JAMA oncology 3 (9), 1197-1203, 2017 | 549 | 2017 |
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations AW Langerak, PJTA Groenen, M Brüggemann, K Beldjord, C Bellan, ... Leukemia 26 (10), 2159-2171, 2012 | 533 | 2012 |
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value BA Walker, PE Leone, L Chiecchio, NJ Dickens, MW Jenner, KD Boyd, ... Blood, The Journal of the American Society of Hematology 116 (15), e56-e65, 2010 | 471 | 2010 |
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total … A Dewdney, D Cunningham, J Tabernero, J Capdevila, B Glimelius, ... Journal of Clinical Oncology 30 (14), 1620-1627, 2012 | 461 | 2012 |
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial D Gonzalez, P Martinez, R Wade, S Hockley, D Oscier, E Matutes, ... Journal of Clinical Oncology 29 (16), 2223-2229, 2011 | 382 | 2011 |
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 PAS Evans, C Pott, P Groenen, G Salles, F Davi, F Berger, JF Garcia, ... Leukemia 21 (2), 207-214, 2007 | 361 | 2007 |
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ... Journal of Thoracic Oncology 5 (10), 1706-1713, 2010 | 358 | 2010 |
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 351 | 2014 |
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma D González, M van der Burg, R García-Sanz, JA Fenton, AW Langerak, ... Blood, The Journal of the American Society of Hematology 110 (9), 3112-3121, 2007 | 326 | 2007 |
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t (4; 14) and t (11; 14) myeloma BA Walker, CP Wardell, L Melchor, S Hulkki, NE Potter, DC Johnson, ... Blood, The Journal of the American Society of Hematology 120 (5), 1077-1086, 2012 | 315 | 2012 |
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance D Gonzalez de Castro, PA Clarke, B Al‐Lazikani, P Workman Clinical Pharmacology & Therapeutics 93 (3), 252-259, 2013 | 313 | 2013 |
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis FE Davies, AM Dring, C Li, AC Rawstron, MA Shammas, SM O'Connor, ... Blood 102 (13), 4504-4511, 2003 | 313 | 2003 |
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia S Pospisilova, D Gonzalez, J Malcikova, M Trbusek, D Rossi, AP Kater, ... Leukemia 26 (7), 1458-1461, 2012 | 290 | 2012 |
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial DG Oscier, MJJ Rose-Zerilli, N Winkelmann, D Gonzalez de Castro, ... Blood, The Journal of the American Society of Hematology 121 (3), 468-475, 2013 | 282 | 2013 |
Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and … AG Nicholson, D Gonzalez, P Shah, MJ Pynegar, M Deshmukh, A Rice, ... Journal of Thoracic Oncology 5 (4), 436-441, 2010 | 271 | 2010 |
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a … M Brüggemann, M Kotrova, H Knecht, J Bartram, M Boudjogrha, V Bystry, ... Leukemia 33 (9), 2241-2253, 2019 | 253 | 2019 |
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry ME Sarasquete, R García-Sanz, D González, J Martínez, G Mateo, ... haematologica 90 (10), 1365-1372, 2005 | 244 | 2005 |
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, ... Leukemia 32 (5), 1070-1080, 2018 | 237 | 2018 |